(Q39221724)

10 September 2017

title

Medrogestone: a prospective study in the pharmaceutical management of benign prostatic hyperplasia (English)

1 reference

10 September 2017

Medrogestone: A Prospective Study in the Pharmaceuticalmanagement of Benign Prostatic Hyperplasia (English)

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

18 September 2023

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

18 September 2023

author name string

D. F. Paulson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1097740

18 September 2023

R. D. Kane

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1097740

18 September 2023

language of work or name

English

0 references

publication date

1 June 1975

1 reference

full work available at URL

10 September 2017

https://api.elsevier.com/content/article/PII:S0022534717595853?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

https://api.elsevier.com/content/article/PII:S0022534717595853?httpAccept=text/plain

18 September 2023

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

http://www.jurology.com/doi/pdf/10.1016/S0022-5347%2817%2959585-3

18 September 2023

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

18 September 2023

1 reference

10 September 2017

volume

113

1 reference

10 September 2017

issue

6

1 reference

10 September 2017

page(s)

811-815

1 reference

A Study of the Effect of Stilbestrol Therapy on the Size of the Benignly Hypertrophied Prostate Gland

10 September 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

Hormonal management of the benign obstructing prostate: use of combined androgen-estrogen therapy

18 September 2023

4

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

Treatment of benign prostatic hypertrophy with medrogestone

18 September 2023

5

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH HYDROXYPROGESTERONE CAPROATE: EFFECT ON CLINICAL SYMPTOMS, MORPHOLOGY, AND ENDOCRINE FUNCTION.

18 September 2023

6

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate

18 September 2023

8

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

Treatment of Benign Prostatic Hypertrophy with Progestational Agents: A Preliminary Report

18 September 2023

9

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

Medrogestone therapy in advanced endometrial adenocarcinoma

18 September 2023

10

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

Biological activity of medrogestone: a new orally active progestin

18 September 2023

13

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)59585-3

18 September 2023

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1097740

18 September 2023

1 reference